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INTRODUCTION
Aldo-keto reductases (AKRs) and carbonyl reductases (CBRs) are members of a highly divergent superfamily of NAD(P)H-dependent oxidoreductase enzymes that have been shown to metabolize a broad range of endogenous and exogenous carbonyl-containing compounds, including steroid hormones, aflatoxins, sugar/lipid aldehydes, and prostaglandins (Matsunaga et al., 2006; Hoffmann and Maser, 2007; Jin and Penning, 2007; Penning and Drury, 2007) . AKRs and CBRs are categorized as Phase I metabolizing enzymes responsible for converting compounds containing reactive aldehyde and ketone functional groups to their corresponding hydroxy metabolites. This metabolic conversion increases the water solubility of the metabolites, and facilitates their elimination from the body directly or via Phase II conjugation reactions.
In addition to the aforementioned compounds, AKRs and CBRs have also been implicated in the metabolism of the anthracycline antibiotics, daunorubicin (DAUN) and doxorubicin (DOX) (Cummings et al., 1991; Jin and Penning, 2007) . DAUN and DOX rank among the most effective antineoplastic agents ever developed in cancer therapy (Lakhman et al., 2005; Blanco et al., 2008) . DAUN plays a vital role in the treatment of acute myeloid and lymphoblastic leukemias, while DOX is extensively employed against numerous cancers, including breast cancer, childhood solid tumors, non-Hodgkin's lymphoma, and soft tissue JPET#173179 of chronic cardiotoxicity increases when DOX and DAUN are used in combination with other anticancer drugs, such as herceptin, paclitaxel, docetaxel, vincristine, and cyclophosphamide (Mordente et al., 2001; Danesi et al., 2002; Floyd et al., 2005; Gianni et al., 2007) .
The cause of the inter-patient variation in DAUN or DOX-induced adverse events is unknown. However, non-synonymous single nucleotide polymorphisms (ns-SNPs) in the genes expressing enzymes that metabolize these anthracyclines may be one factor contributing to this inter-patient variable toxicity. Previous in vitro studies demonstrated that ns-SNPs in human AKR1A1, CBR1 and CBR3 genes produce enzymes with significantly reduced metabolism of DAUN and/or DOX compared to their wild-type counterparts (Bains et al, 2008; Bains et al., 2009 : Bains et al., 2010 . To test this hypothesis, we examined whether variant enzymes generated by ns-SNPs in eight other human AKR and CBR genes (AKR1B1, 1B10, 1C1, 1C2, 1C3, 1C4, 7A2, and CBR4) significantly impact their ability to metabolize DAUN or DOX. The AKRs were selected because prior experiments have shown that the wild-type enzyme was able to metabolize DOX and/or DAUN (Ohara et al., 1995; O'Connor et al., 1999; Martin et al., 2006; Kassner et al., 2008) . CBR4 was included in this study because this CBR isoform is the only one remaining for which there is no published data on its ability to metabolize DOX and DAUN. The CBR1, 3, and 4 genes encode the three distinct isoforms of the CBR enzymes that are found in humans (Hoffmann and Maser, 2007; Oppermann 2007; Endo et al., 2008) .
The purpose of this study is to improve our understanding of the effect of genetic variation in the human AKR and CBR4 genes on the in vitro metabolism of DOX, DAUN, and standard test substrates. Presently, there are 28 documented ns-SNPs in these genes in the human genome, as listed in the National Centre for Biotechnology Information Database. The frequencies of these variant alleles among different populations range from 0.8 to 62.5% (Table JPET#173179   6 1). Using purified, bacterially-expressed, human histidine-tagged enzymes, we compared the metabolic capability of the wild-type and variants by monitoring the formation of the corresponding carbon-13 alcohol metabolites, daunorubicinol (DAUNol) and doxorubicinol (DOXol) . We demonstrated that certain variants of AKR1C3 (A106T, R170C, and P180S), AKR1C4 (L311V), and AKR7A2 (A142T) significantly reduced DAUN and DOX metabolism compared to the wild-type enzymes based on the following kinetic parameters: V max (DAUN: 23-61% decrease, DOX: 41-44% decrease), K m (156% and 47% increase with the A142T variant in presence of DAUN and DOX, respectively), k cat (DAUN: 22-61% decrease, DOX: 39-45% decrease), and k cat /K m (DAUN: 38-85% decrease, DOX: 52-69% decrease). Furthermore, after comparing k cat /K m values between these two drugs among the wild-type and variant enzymes, we observed that DAUN is generally a better substrate for the AKRs while DOX is a better substrate for CBR4.
This article has not been copyedited and formatted. The final version may differ from this version. The human AKR1C3 wild-type coding region was excised from a pOTB7 recombinant plasmid (Invitrogen, Carlsbad, CA) using XmnI and DdeI (blunt end with Klenow fragment) and subcloned into HindIII (blunt end)-XhoI (blunt end) sites of the pET28a prokaryotic expression vector (EMD, Novagen, San Diego, CA) with T4 ligase. This construct gave rise to a human AKR1C3 enzyme with an amino terminal 6x-His tag separated from the enzyme by a 32-amino acid residue linker. A FXa cleavage site and methionine start site were inserted at the amino terminus between the linker and AKR1C3 gene using the QuikChange The human AKR1B10 and CBR4 wild-type coding regions were PCR amplified from a pOTB7 (Invitrogen) and pCMV-SPORT6 (Invitrogen) recombinant plasmid, respectively, using the following primers, which contained an EcoRI adapter in the forward primers and a XhoI adapter in the reverse primers (adapters are underlined): 5' -GTACCGCTCGAATTCATGGCCACGTTTGTGG -3' (forward) and 5' -GTCTGCTACCTCGAGTCAATATTCTGCATCG -3' (reverse) for AKR1B10 and 5' -This article has not been copyedited and formatted. The final version may differ from this version. The construct with the AKR7A2 gene included a ns-SNP at position 142 resulting in a change from alanine to threonine, which turned out to be one of the variants that we used in this study. Therefore, we performed site directed mutagenesis as described above with the following primers to generate the wild-type gene: 5' -CTTCTACCTACACGCACCTGACCACG -3' (forward) and 5' -CGTGGTCAGGTGCGTGTAGGTAGAAG -3' (reverse). This construct (Schlegel et al., 1998; Di Luccio et al., 2006; Jin and Penning, 2007) . Therefore, it was assumed that the protein would be inactive.
Expression and purification of recombinant human AKR and CBR4 wild-type and variant enzymes:
The pET constructs of the AKR and CBR4 wild-type and variants were heat-shock transformed into Escherichia coli BL21 (DE3) pLysS competent cells and expressed under the control of an IPTG-inducible T7 polymerase. Cells were plated on Luria-Bertani broth agar (1% bacto-tryptone, 0.5% yeast extract, 0.5% NaCl) supplemented with antibiotics (25 µg/ml chloramphenicol and 50 µg/ml kanamycin sulphate for the pET28a constructs or 100 µg/ml ampicillin for the pET15b constructs). Colonies were randomly picked and cultured overnight at The cells containing the recombinant 6x-His tagged AKR enzymes were resuspended at 5 ml per gram wet weight with Buffer A (300 mM NaCl, 50 mM NaH 2 PO 4 , pH 8.0). The cell suspension was lysed with lysozyme (final concentration of 1 mg/ml, incubated on ice for 30 min), and subsequently disrupted using six 10-sec bursts (with a 10 sec cooling period between each burst) from a sonic dismembranator with a microtip set at 200-300 W. This was followed by incubation with DNaseI and RNAseI (5 and 10 µg/ml, respectively) for 15 min on ice and then centrifuged (10,000xg, 20 min, 4 o C). The cell lysate was subjected to nickel-nitrilotriacetic acid affinity (Ni-NTA) chromatography in order to isolate the recombinant proteins (Bains et al., 2008) . Ultimately, the AKRs were eluted using multiple fractions of Buffer A with increasing concentrations of imidazole (30, 50, 100 and 250 mM).
Cells containing the recombinant 6x-His tagged CBR4 enzymes were resuspended in Buffer B (100 mM NaH 2 PO 4 , 10 mM Tris-Cl, pH 8.0) with 8 M urea for lysis. The extracted CBR4 proteins were subjected to purification by Ni-NTA chromatography under denaturing conditions according to the QIAGEN protocol. In the end, CBR4 was eluted using multiple fractions of Buffer B with decreasing pH levels (6.3, 5.9 and 4.5). The eluted fractions were then dialyzed at 4 o C to gradually remove the urea (Buffer B with 6 M, 4 M, 2 M and 1 M urea for 2 hrs each followed by 0 M urea overnight).
Protein purity was assessed by running elution fractions on 18% SDS-polyacrylamide gels, which were stained with SYPRO ® Ruby (Invitrogen Canada, Inc., Burlington, ON) overnight (16 hrs). After staining, the protein was detected using a Storm 840 Molecular
This article has not been copyedited and formatted. The final version may differ from this version. Both primary and secondary antibodies were in blocking buffer containing 0.1% Tween 20. The bound secondary antibody was detected using the Odyssey TM Infrared Imaging system (LI-COR).
Enzymatic activity of AKR and CBR4 enzymes in presence of test substrates:
The enzyme activities of the purified 6x-His tagged AKR and CBR4 wild-type and variant enzymes were measured using a Fluoroskan Ascent FL (Thermo Fisher Scientific, Waltham, MA) by following the initial rate of either NADPH oxidation or NADP + reduction (depending on the test substrate) at excitation and emission wavelengths of 355 and 460 nm, respectively. The assays were conducted using 1-acenaphthenol (for AKR1C isoforms), DLglyceraldehyde (for AKR1B1), (S)-1-indanol (for AKR1B10), 9,10-phenanthrenequinone (for AKR7A2), and menadione (for CBR4) as test substrates (Burczynski et al., 1998 Martin et al., 2006; Takahashi et al., 2008; Byrns et al., 2008; Endo et al., 2008) . In brief, 3 µg purified protein was incubated with 2.3 mM NADP + or 0.2 mM NADPH and test substrate (1 mM acenapthenol and DL-glyceraldehyde, 0.5 mM (S)-1-indanol, 0.05 mM 9,10-phenanthrenquinone, and 5-500 µM menadione) in a reaction mixture of 150 µl of 100 mM KH 2 PO 4 , pH 7.4. Assays involving AKR1B1, AKR1C1, AKR1C2, AKR1C3, and AKR7A2, and CBR4 were performed at 25 o C while assays with the remaining enzymes were conducted at 37 o C (these were the temperatures at which the assays were performed in the aforementioned published literature with the test substrates). In these assays, the concentration of DMSOmethanol (4:1 mixture), which was required to dissolve the substrates (except for DLglyceraldehyde for which water was used) was kept below 4% (v/v) in the final reaction mixture.
Readings were collected at 20-sec intervals for 1.5 hrs with shaking between each reading.
Maximal rates were calculated from the Ascent program (version 2.6) using a 5-min interval (15 total readings) with the steepest slope. The enzymatic activity was calculated from the maximal rates using a standard curve constructed from the fluorescence measurements of solutions of known NADPH concentrations. Enzyme activity in the presence of 1-acenapthenol and (S)-1-indanol was measured as nanomoles of NADP + reduced per minute per milligram of purified protein while activity for the other substrates were measured as nanomoles NADPH oxidized per minute per milligram of purified protein. Activities were ascertained and compared with published rates to determine if the purified enzymes were functional.
Kinetic activity of AKR and CBR4 enzymes in the presence of anthracyclines:
Activity measurements for the reduction of the anthracyclines were performed by incubating either DOX or DAUN (50-700 µM; in some cases up to 1000 µM) with 3 µg purified This article has not been copyedited and formatted. The final version may differ from this version. Following Michaelis-Menten data analysis, Eadie-Hofstee plots were generated to check for deviation from linearity with changing substrate concentrations.
Statistical analysis:
Statistical analyses were performed using GraphPad Instat ® (version 3.6; GraphPad Software Inc., San Diego, CA). Results were expressed as means ± S.D. Enzyme activities were compared using a one-way analysis of variance followed by Tukey-Kramer multiple comparisons tests. Differences were considered significant at p<0.05.
This article has not been copyedited and formatted. The final version may differ from this version. 
RESULTS
Expression and purification of human AKR and CBR4 wild-type enzymes and variants:
The expression of the 6x-His tagged recombinant human AKR and the CBR wild-type enzymes were confirmed by Western blot analyses, which showed a band with mobility corresponding to the calculated molecular mass of the tagged AKR or CBR protein (38.5 kDa for AKR1B1, 40.3 kDa for AKR1B10, 39.4 kDa for AKR1C1, 40.2 kDa for AKR1C2, 41.9 kDa for AKR1C3, 39.7 kDa for AKR1C4, 39.3 kDa for AKR7A2, and 29.5 kDa for CBR4) (Supplemental Fig. 1 ). Total protein staining of the SDS-PAGE gel demonstrated that the wildtype fraction was purified from its transformed bacterial lysate, since no other proteins were detected (Supplemental Fig. 1 ). For the AKR wild-type and variant enzymes, the majority of pure enzyme was recovered in the 250 mM imidazole elution fractions; no further protein was eluted with higher imidazole concentrations. For the CBR4 wild-type and variant enzymes, the majority of pure enzyme was recovered in the pH 4.5 elution fractions following protein purification under denaturing conditions with 8 M urea. The results for the expression and purification of the variant forms of each enzyme paralleled that of the corresponding wild-type enzyme (data not shown).
Enzymatic rates of AKR and CBR4 wild-type and variants with test substrates:
Enzymatic rates for the AKR1C isoforms were determined using 1-acenaphthenol as a standard test substrate while 9,10-phenanthrenequinone, DL-glyceraldehyde, (S)-1-indanol, and menadione were used to calculate AKR7A2, AKR1B1, AKR1B10, and CBR4 activity, respectively (Table 2) . A total of six 6x-His tagged variants exhibited significantly reduced activity rates compared to their corresponding wild-type enzymes. In the presence of 1-This article has not been copyedited and formatted. The final version may differ from this version. Table 2 ). Three of the five variants for AKR1C3 (A106T, R170C and P180S) were found to have significantly lower rates compared to the wildtype (29 to 39% lower). Also, the F46Y and L311V variants had significantly lowered enzymatic rates compared to their respective AKR1C2 and AKR1C4 wild-types (30-42% lower).
For the 6x-His tagged AKR7A2 wild-type enzyme, the rate was found to be 2553±229 nmol NADPH oxidized/min•mg purified protein, which parallels the published rate of 3100±107 nmol/min•mg using 9,10-phenanthrenequinone. Only one variant (A142T) was found to have significantly reduced enzymatic rate compared to the wild-type AKR7A2 (35% lower Fig. 2 ). There were no significant differences in enzymatic activity between the tagged and native AKR1C using 1-acenaphthenol as substrate [rates of the native enzymes were 1800±130, 2710±140, 3060±210, and 1500±210 nmol/min•mg for AKR1C1, AKR1C2, AKR1C3, and AKR1C4, respectively], suggesting that the amino acid linker and 6x-His tag engineered on the amino terminus of the wild-type gene products has no effect on enzyme activity. Likewise, we found similar results between the tagged and native AKR1B isoforms, AKR7A2, and CBR4 enzymes
[rates of the native enzyme were 300±50 (AKR1B1), 910±40 (AKR1B10), and 2550±250 we did not cleave off the tag and linker for the variants, we assumed that there would be no significant difference between the rates of the tagged and untagged variant enzymes. Keeping these results and assumptions in mind, the uncleaved wild-type and variant enzymes were used for subsequent activity assays using the anthracyclines as substrates.
Kinetic characterization of AKR and CBR4 wild-type and variant enzymatic activities with DOX and DAUN as substrates:
We measured the in vitro formation of the major alcohol metabolites to evaluate the of enzymatic activity for each of the concentrations of DOX and DAUN used to conduct the enzymatic assays (3 µg purified protein). In addition, the concentration of cofactor (1 mM NADPH) was sufficient for maximal enzymatic activity during this 50 min incubation period.
Higher concentrations of cofactor were also examined (1.5 mM and 2 mM); however, the enzymatic rates associated with these concentrations did not differ from that of 1 mM (data not shown).
Full chromatographic resolution of DAUNol, DOXol, DAUN, DOX, and idarubicin (internal standard) was achieved for all chemical standards and in vitro samples (Bains et al., 2008) . DOXol, DOX, DAUNol, DAUN, and idarubicin were observed to elute at 4.6, 5.5, 6.1, 6.9, and 7.4 min, respectively. Incubation of the 6x-His tagged AKR and CBR4 wild-type and variant enzymes with DOX generated a single new chromatographic peak that was identified as DOXol. Similarly, incubating the AKR and CBR4 wild-type and variant enzymes with DAUN generated a single new chromatographic peak that was identified as DAUNol. The identification of the metabolite peaks was confirmed by incubation of DOX and DAUN with human liver cytosol and the generation of compounds that had identical chromatographic behaviors. There were no detectable peaks at the DAUNol or DOXol retention time in the absence of the AKR and CBR4 proteins. In addition to the enzymatic assays performed in this study, we incubated enzyme only as well as enzyme and substrate without the addition of cofactor, as controls. The production of DOXol and DAUNol from these controls were below the limit of detection (25 nM) using HPLC-fluorescence. Therefore, we conclude the production of the alcohol metabolites is due to enzymatic processes.
Michaelis-Menten kinetic curves were constructed for the AKR wild-type ( Fig. 1) 
DISCUSSION
The focus of this study was to examine the effect of ns-SNPs on the enzymatic activity of human AKR and CBR4 using test substrates, as well as DAUN and DOX. The wild-type and variant alleles of these genes were cloned into an E. coli expression vector with a 6x-His tag added to the amino terminus of the expressed protein. The respective wild-type and variant proteins for each gene were purified and purity assessed by electrophoretic and Western blot analyses. To determine whether the 6x-His tag influenced enzyme activity, the tag was removed by incubation with FXa and the enzyme repurified. Using the test substrates, the activity of the tagged enzyme did not significantly differ from its native counterpart. Therefore, we were able to assess the impact of the single amino acid substitutions on the activity of each enzyme, without cleaving the tag in the subsequent assays involving DAUN and DOX.
DOXol and DAUNol, which are the carbon-13 alcohol metabolites of DOX and DAUN, respectively, were quantified in these assays, since previous published studies demonstrated that they are the major metabolites in cancer patients receiving treatment with either of these anthracycline anti-cancer drugs (Lipp and Bokemeyer, 1999; Plebuch et al., 2007) . Our assays show that both drugs are converted to their respective major metabolites by the wild-type and variants enzymes for the reductases examined in this study.
Out of the 27 allelic variants that were studied (excluding the E36Term truncated variant), respective wild-type enzyme: R170C, P180S and A142T. To our knowledge, this study is the first demonstration of the effect of these variant enzymes on DAUN and DOX metabolism.
We used three-dimensional models of human AKR1C3, AKR1C4 and AKR7A2 enzymes (Fig. 3) to examine the location of the five mutations relative to the active and cofactor binding sites. Reduction of the carbonyl group by AKR enzymes is thought to involve the co-operation of four amino acids (tyrosine, lysine, aspartic acid and histidine) forming a catalytic tetrad, which are positionally conserved in the individual reductases within this superfamily (Jez et al., 1997; Penning 2003; Barski et al., 2008) . The locations of these conserved residues for the three therefore help anchor the cofactor to the AKR1C3 enzyme (Komoto et al., 2004) . It is possible that these mutations affect the binding of the cofactor, which ultimately reduces the enzymatic conversion of DAUN and DOX to DAUNol and DOXol, respectively. It is, however, possible that the P180S mutation could alter the active site since its effect on metabolism appears greater for DOX (~70% decrease in activity versus the AKR1C3 wild-type) than DAUN (~30% decrease). Currently, there is no data to indicate why or how the A106T polymorphism affects cofactor or substrate binding. We speculate that the chemical structural differences between the This article has not been copyedited and formatted. The final version may differ from this version. Previous studies have shown the importance of leucine-311 in substrate binding to human AKR1C4. For example, a study by Matsuura et al., (1998) , which used chimeric enzymes produced by switching the C-terminal loop in AKR1C4 with that of AKR1C1, demonstrated that the binding of substrates, inhibitors and activators of AKR1C4 requires the amino acid residues located in the C-terminal loop of the wild-type AKR1C4 enzyme, such as leucine-311.
Furthermore, the authors found that a leucine to valine mutation in amino acid 311 (L311V) decreased the catalytic activity of AKR1C4 for its substrates, but it did not affect the enzyme's sensitivity to an inhibitor or affect the enzyme's response to an activator. Hence, this study suggested that leucine-311 is important in substrate binding to the active site of the AKR1C4 enzyme. This finding was further substantiated in a study by Kume et al., (1999) , which used purified recombinant human AKR1C4 enzymes to show that the L311V polymorphism resulted in a 3-to 5-fold decrease in enzyme activity compared to the wild-type for a variety of xenobiotic and steroidal substrates. Besides the effect of L311V, this study also revealed that the S145C ns-SNP (serine to cysteine mutation at amino acid position 145) had no significant effect on enzyme activity compared to the wild-type for a variety of xenobiotic and steroidal substrates.
Our study demonstrates that the L311V mutation dramatically alters the ability of the enzyme to metabolize DAUN and DOX and, like the previous studies on xenobiotic and steroidal substrates, indicates that the S145C mutation has little affect on the ability of the enzyme to use DAUN and DOX as substrates.
The alanine to threonine mutation at amino acid position 142 in human AKR7A2 (the A142T ns-SNP) is adjacent to the histidine-141 residue, which is one of the four amino acids that forms a catalytic tetrad for reduction of the substrate (others being tyrosine-77, lysine-105, and aspartic acid-72). Due to this proximity, the A142T polymorphism may hinder the ability of histidine-141 to participate in catalysis of DOX and DAUN, thus, leading to reduced enzymatic activity compared to the wild-type AKR7A2 enzyme.
In addition to looking at the differences in enzyme activity between the wild-type and variant enzymes with both anthracyclines, our studies demonstrated that DAUN was generally a better substrate for all wild-type and variant forms of the human AKRs (except AKR1C2), as
shown by 1.9-to 257-fold increases in k cat /K m over DOX. On the other hand, CBR4 and its variant metabolize DOX far more efficiently than DAUN, as seen by increases of 31.9-to 40-fold in k cat /K m for DOX over DAUN. Catalytic efficiencies for both DAUN and DOX were also compared between the wild-type AKRs and CBRs (Fig. 5) . For comparison purposes, k cat /K m values for human recombinant 6x-His tagged CBR1 and CBR3 (Bains et al., 2010) were incorporated, along with human 6x-His tagged AKR1A1 (same as in Bains et al., 2008) , for which we expressed, purified, and performed extensive Michaelis-Menten analysis with DAUN and DOX using the same protocols described in this study (DAUN: In conclusion, this study, along with our previous in vitro studies involving AKRs and CBRs, demonstrates that these enzymes are able to metabolize both DAUN and DOX, with the AKRs and CBR1 generally having higher specificity for the DAUN and CBR3 and CBR4 for DOX. Significant reductions in enzyme activity were discovered in twelve variants for all the AKRs and CBRs studied: five variants of AKR1C3, AKR1C4 and AKR7A2 in this study, along with seven variants of AKR1A1 (N52S and E55D), CBR1 (V88I and P131S), and CBR3 (C4Y, V93I, and V244M) in other studies (Bains et al., 2008; Bains et al., 2009; Bains et al., 2010) .
Mutations in genes encoding these enzymes may contribute to the inter-patient variability seen with the development of serious cardiac side effects in DAUN-and DOX-treated patients. If
AKRs and CBRs play a major role in anthracycline-induced cardiotoxicity, we propose that this condition is largely the result of accumulation of the parent drug. This may be true since the AKR and CBR isoforms, with variants exhibiting significantly reduced activity towards DAUN and/or DOX, are expressed in human heart tissue ( Table 5 ; Supplemental Fig. 3 ). The data collected in this study begs the question of whether individuals bearing one or more of the previously mentioned AKR and CBR polymorphisms are at higher risk for developing cardiac side effects after treatment with either of these anthracyclines. This issue can be addressed with clinical association studies, which are currently underway in our laboratory to determine whether there is a correlation with cardiotoxicity. a k cat calculated from M r 38500 (AKR1B1), 40300 (AKR1B10), 39400 (AKR1C1), 40200 (AKR1C2), 41900 (AKR1C3), 39700 (AKR1C4), 39300 (AKR7A2), and 29600 (CBR4).
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